WO2015123439A3 - Methods of promoting neuroblast differentiation and treating neuroblastoma and of providing a prognosis for subjects with neuroblastoma - Google Patents

Methods of promoting neuroblast differentiation and treating neuroblastoma and of providing a prognosis for subjects with neuroblastoma Download PDF

Info

Publication number
WO2015123439A3
WO2015123439A3 PCT/US2015/015667 US2015015667W WO2015123439A3 WO 2015123439 A3 WO2015123439 A3 WO 2015123439A3 US 2015015667 W US2015015667 W US 2015015667W WO 2015123439 A3 WO2015123439 A3 WO 2015123439A3
Authority
WO
WIPO (PCT)
Prior art keywords
neuroblastoma
prognosis
methods
subject
subjects
Prior art date
Application number
PCT/US2015/015667
Other languages
French (fr)
Other versions
WO2015123439A2 (en
Inventor
Gerard C. BLOBE
Erik H. KNELSON
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of WO2015123439A2 publication Critical patent/WO2015123439A2/en
Publication of WO2015123439A3 publication Critical patent/WO2015123439A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Methods of promoting neuroblast differentiation in subjects with neuroblastoma by administering an. agent to a subject with neuroblastoma are provided herein. The agent may be a heparin -sulfate proteoglycan co-receptor, heparin sulfate or a heparin analog. Promotion of neuroblast differentiation, may suppress neuroblast growth and treat neuroblastoma... Methods of determining a prognosis for a subject with neuroblastoma are also provided. The methods include measuring the level of at least one marker selected from FGF2, FGFR1, ID1, TβRIII, SDC3, SDC4, GPC3 and GPC1 in a sample from the subject and comparing the level in the subject to a reference level. If the levels of any of the markers are higher than the reference level the subject has a good prognosis. If the levels are lower than the reference level, the prognosis is poor.
PCT/US2015/015667 2014-02-12 2015-02-12 Methods of promoting neuroblast differentiation and treating neuroblastoma and of providing a prognosis for subjects with neuroblastoma WO2015123439A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461938802P 2014-02-12 2014-02-12
US61/938,802 2014-02-12

Publications (2)

Publication Number Publication Date
WO2015123439A2 WO2015123439A2 (en) 2015-08-20
WO2015123439A3 true WO2015123439A3 (en) 2015-11-12

Family

ID=53800754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/015667 WO2015123439A2 (en) 2014-02-12 2015-02-12 Methods of promoting neuroblast differentiation and treating neuroblastoma and of providing a prognosis for subjects with neuroblastoma

Country Status (1)

Country Link
WO (1) WO2015123439A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106282122B (en) * 2016-08-23 2020-10-02 中国科学院上海药物研究所 Method for establishing animal model of phobia of non-human mammal or related diseases thereof and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723698B2 (en) * 1991-03-11 2004-04-20 Curis, Inc. Methods and compositions for the treatment of motor neuron injury and neuropathy
US20050287541A1 (en) * 2003-09-25 2005-12-29 Hisamitsu Pharmaceutical Co., Inc. Microarray for predicting the prognosis of neuroblastoma and method for predicting the prognosis of neuroblastoma
US20110250192A1 (en) * 2008-08-01 2011-10-13 Academia Sinica Use of microrna signatures for assessing risk levels of neuroblastoma patients

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723698B2 (en) * 1991-03-11 2004-04-20 Curis, Inc. Methods and compositions for the treatment of motor neuron injury and neuropathy
US20050287541A1 (en) * 2003-09-25 2005-12-29 Hisamitsu Pharmaceutical Co., Inc. Microarray for predicting the prognosis of neuroblastoma and method for predicting the prognosis of neuroblastoma
US20110250192A1 (en) * 2008-08-01 2011-10-13 Academia Sinica Use of microrna signatures for assessing risk levels of neuroblastoma patients

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KIM ET AL.: "Fibroblast growth factor 2 induces differentiation and apoptosis of Askin tumour cells", JOURNAL OF PATHOLOGY, vol. 202, 27 November 2003 (2003-11-27), pages 103 - 112, XP055237505 *
KNELSON ET AL.: "Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 124, 17 June 2014 (2014-06-17), pages 3016 - 3031, XP055237508 *
KNELSON ET AL.: "Type III TGF-beta receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 123, no. 11, November 2013 (2013-11-01), pages 4786 - 4798, XP055237492 *
PIJUAN-THOMPSON ET AL.: "Retinoic Acid Alters the Mechanism of Attachment of Malignant Astrocytoma and Neuroblastoma Cells to Thrombospondin-1", EXPERIMENTAL CELL RESEARCH, vol. 249, 1999, pages 89 - 101, XP055237495 *

Also Published As

Publication number Publication date
WO2015123439A2 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
NZ718962A (en) Cancer models and associated methods
GB2569922A (en) Measurement of edema
MX356802B (en) Biological markers for identifying patients for treatment with vegf antagonists.
WO2016040775A8 (en) Apparatus and methods for identifying and evaluating bright spot indications observed through optical coherence tomography
MY192917A (en) Compositions and methods of use for treating metabolic disorders
SG10201809428UA (en) Insulin receptor partial agonists
MY170983A (en) Biomarker assays for detecting or measuring inhibition of tor kinase activity
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
EP3403109A4 (en) Probes with fiducial marks, probe systems including the same, and associated methods
GB2574997A (en) Multi-factor document analysis
AU335410S (en) Animal trap
NZ731141A (en) New dextran sulfate
MX2018000303A (en) System and method of assessing endothelial function.
AU335450S (en) Animal trap
WO2015158890A3 (en) Pancreatic cancer therapy and diagnosis
WO2014140362A3 (en) Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)
WO2014152754A3 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
AU201817488S (en) Collecting or testing cup
MX2015009696A (en) Stable compositions comprising heparinoid, acute-acting anesthetic, and buffer.
WO2015123439A3 (en) Methods of promoting neuroblast differentiation and treating neuroblastoma and of providing a prognosis for subjects with neuroblastoma
ES2672989T3 (en) FALZ for use as a target for therapies to treat cancer
MX2015009606A (en) A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications.
MX358340B (en) Extracts from mother-of-thyme and the use thereof.
EP3813651A4 (en) Systems and methods for normalizing signals in blood culture measurement systems
WO2015036643A3 (en) Marker for predicting metastasis of breast cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15749207

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15749207

Country of ref document: EP

Kind code of ref document: A2